The company smashed estimates for the quarter and hiked its revenue outlook once again. It now expects sales of 85 billion to 87 billion, up from a previous outlook of 82 billion to 85 billion. Sales jumped 48% this quarter thanks to higher demand for Zepbound and Munjaro, which helped offset those lower prices of those treatments in the US.And Munjara almost topped 10 billion in sales for the first time. And we're seeing strong demand for that drug internationally. One thing I'll highlight is that this is ...